Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context

This real-world study in France is tracking how well lorlatinib — a targeted therapy for lung cancer — works in everyday clinical practice for patients with ALK-positive non-small cell lung cancer (NSCLC) who have not yet received any treatment. **You may be eligible if...** - You are 18 or older - You have been diagnosed with locally advanced or metastatic NSCLC and your tumor tests positive for the ALK gene change (by IHC or FISH) - You have not yet received any ALK-targeted therapy - You have had a complete scan (CT of chest/abdomen and brain MRI) before starting lorlatinib - You have a good to moderate performance status (ECOG 0-2) **You may NOT be eligible if...** - You have another active cancer (within the last 2 years, with some exceptions) - You have previously received any ALK-targeted drug as adjuvant therapy (unless relapse happened more than a year later) - You have already received systemic therapy for your advanced/metastatic NSCLC Talk to your doctor to see if this trial is right for you.